Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Hironori Yamaguchi
Based on 3 articles published since 2010
(Why 3 articles?)
||||

Between 2010 and 2020, Hironori Yamaguchi wrote the following 3 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Clinical Trial Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. 2016

Takahara, Naminatsu / Isayama, Hiroyuki / Nakai, Yousuke / Ishigami, Hironori / Satoi, Sohei / Mizuno, Suguru / Kogure, Hirofumi / Matsubara, Saburo / Yamamoto, Natsuyo / Yamaguchi, Hironori / Tada, Minoru / Kitayama, Joji / Watanabe, Toshiaki / Koike, Kazuhiko. ·Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. · Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. isayama-tky@umin.ac.jp. · Department of Chemotherapy, The University of Tokyo, Tokyo, Japan. · Department of Surgery, Kansai Medical University, Osaka, Japan. · Department of Surgery, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan. · Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan. ·Invest New Drugs · Pubmed #27339809.

ABSTRACT: CLINICAL TRIAL REGISTRATION NUMBER: UMIN000005306).

2 Clinical Trial Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. 2014

Takahara, Naminatsu / Isayama, Hiroyuki / Nakai, Yousuke / Sasaki, Takashi / Ishigami, Hironori / Yamashita, Hiroharu / Yamaguchi, Hironori / Hamada, Tsuyoshi / Uchino, Rie / Mizuno, Suguru / Miyabayashi, Koji / Mohri, Dai / Kawakubo, Kazumichi / Kogure, Hirofumi / Yamamoto, Natsuyo / Sasahira, Naoki / Hirano, Kenji / Ijichi, Hideaki / Tateishi, Keisuke / Tada, Minoru / Kitayama, Joji / Watanabe, Toshiaki / Koike, Kazuhiko. ·Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, , Bunkyo-ku, Tokyo, 113-8655, Japan. ·J Gastrointest Cancer · Pubmed #24676891.

ABSTRACT: OBJECTIVES: Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites. METHODS: Paclitaxel was administered intravenously at 50 mg/m2 and intraperitoneally at 20 mg/m2 on days 1 and 8 every 3 weeks, and S-1 was administered at 80 mg/m2/day for 14 consecutive days, followed by 7-day rest. RESULTS: Between April 2011 and February 2012, ten patients were enrolled. A partial response was achieved in two patients (20%) and a disease control rate of 50%. The median time to progression and overall survival were 2.1 and 3.4 months, respectively. Malignant ascites was completely resolved in two patients (20%). Major grade 3/4 adverse events were myelosuppression including neutropenia (50%) and catheter-related infection (10%). CONCLUSIONS: This novel combination chemotherapy was feasible and showed promising results in pancreatic cancer patients with malignant ascites (clinical trial registration number: UMIN000005306).

3 Article Peritoneal metastasis of pancreas cancer mimicking the local recurrence of colon cancer after laparoscopic colectomy. 2017

Nagata, Hiroshi / Yamaguchi, Hironori / Watanabe, Toshiaki. ·Department of Surgical Oncology, The University of Tokyo, Bunkyo, Tokyo, Japan. ·ANZ J Surg · Pubmed #25708002.

ABSTRACT: -- No abstract --